Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) has been mainly studied because of its glucose-dependent insulinotropic action and its ability to regulate beta-cell proliferation and survival. Considerably less is known about the effects of GIP on fat metabolism, and the present study was directed at identifying the mechanisms underlying its stimulatory action on lipoprotein lipase (LPL). In differentiated 3T3-L1 adipocytes, GIP, in the presence of insulin, increased LPL activity and triglyceride accumulation through a pathway involving increased phosphorylation of protein kinase B (PKB) and reductions in phosphorylated LKB1 and AMP-activated protein kinase (AMPK). Knockdown of AMPK using RNA interference and application of the AMPK inhibitor, Compound C, supported this conclusion. In contrast, the other major incretin hormone, glucagon-like peptide-1, exhibited no significant effects on LPL activity or PKB, LKB1, or AMPK phosphorylation. Cultured subcutaneous human adipocytes showed similar responses to GIP but with greater sensitivity. Chronic elevation of circulating GIP levels in the Vancouver diabetic fatty Zucker rat in vivo resulted in increased LPL activity and elevated triglyceride accumulation in epididymal fat tissue, combined with a modulation of PKB, LKB1, and AMPK phosphorylation similar to that observed in vitro. This appears to be the first demonstration of a GIP-stimulated signal transduction pathway involved in increasing fat storage in adipocytes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, treatment of diet-induced obese mice with a GCGR agonist revealed that glucagon-stimulated energy expenditure and weight loss can also be driven by hepatic amino acid catabolism, and thus a systemic response to hypoaminoacidemia74”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [74]
In the citing paper
“However, based on the lipogenetic properties205, 206, 207 of GIP, insufficient insulin-potentiating effects in T2DM patients220, 336 and a possible worsening effect by GIP,337, 338 the focus is on GLP-1 analogues/receptor agonists for T2DM treatment.”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [207]
In the citing paper
“GIP promotes lipogenesis and lipid deposition under conditions of hyperinsulinema [34–36] while stimulating lipolysis and fatty acid oxidation under conditions of normo- or hypoinsulinemia [37–39].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [34]
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
The AMP‐Activated Protein Kinase: Fuel Gauge of the Mammalian Cell?
Hardie, D. G., & Carling, D. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00259.x · Cited by 1,317
The AMP-activated protein kinase cascade – a unifying system for energy control
Carling, D. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.11.005 · Cited by 1,112
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Ram�rez-Zacar�as, J. L., Castro-Mu�ozledo, F., & Kuri-Harcuch, W. (1992) · Histochemistry · doi:10.1007/bf00316069 · Cited by 1,008
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
AMP-Activated Protein Kinase – Development of the Energy Sensor Concept
Hardie, D. G., Hawley, S. A., & Scott, J. W. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108944 · Cited by 813
The regulation of AMP-activated protein kinase by phosphorylation
STEIN, S. C., Woods, A., Jones, N. A., DAVISON, M. D., & Carling, D. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3450437 · Cited by 605
Research works printed but not linked: 7
- Pederson, 2004, Vol. 2, 202
- Knapper, 1995, J. Nutr., 125, 183
- Trümper, 2001, Mol. Endocrinol., 15, 1559
- Stein, 2000, Biochem. J., 345, 437, 10.1042/bj3450437 · DOI · Paper page
- Kim, 2006, Cell. Signal.
- An, 2005, Am. J. Physiol., 288, E246
- Eckel, 1981, Int. J. Obes., 5, 571
Cited by
Items 101–200 of 216
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“79,80 Such chronic agonism promoted the storage of excess energy and improved serum triglyceride and glucose levels in DIO mice, without an increase in adiposity or body weight.”
Loss of intestinal GATA4 prevents diet-induced obesity and promotes insulin sensitivity in mice
Patankar, J. V., Chandak, P. G., Obrowsky, S., Pfeifer, T., Diwoky, C., Uellen, A., Sattler, W., Stollberger, R., Höefler, G., Heinemann, Á., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00457.2010 · Cited by 31
“In another study, it was found that Gip activates lipoprotein lipase on adipocytes and thus enhances lipid deposition (25).”
BackgroundSub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight
Szalowska, E., Meijer, K., Kloosterhuis, N., Razaee, F., Priebe, M. G., & Vonk, R. J. (2011) · Peptides · doi:10.1016/j.peptides.2011.02.011 · Cited by 31
Ohira, M., Miyashita, Y., Murano, T., Watanabe, F., & Shirai, K. (2009) · Metabolism · doi:10.1016/j.metabol.2009.04.024 · Cited by 31
“It is reported that LPL activity in 3T3-L1 adipocytes is increased when AMPK activation is decreased [19,20].”
BackgroundShimazu‐Kuwahara, S., Harada, N., Yamane, S., Joo, E., Sankoda, A., Kieffer, T. J., & Inagaki, N. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.01.006 · Cited by 28
“In addition to stimulating brisk release of insulin [10], GIP promotes adipogenesis and lipid accumulation in adipocytes [11,12].”
BackgroundRazny, U., Kiec-Wilk, B., Polus, A., Goralska, J., Malczewska-Malec, M., Wnek, D., Zdzienicka, A., Gruca, A., Childs, C. E., Kapusta, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.05.001 · Cited by 27
Zelicha, H., Yang, J., Henning, S. M., Huang, J., Lee, R., Thames, G., Livingston, E. H., Heber, D., & Li, Z. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.008 · Cited by 37
Active immunization against (Pro 3 )GIP improves metabolic status in high‐fat‐fed mice
Montgomery, I. A., Irwin, N., & Flatt, P. R. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01228.x · Cited by 27
Fukuoka, D., Okahara, F., Hashizume, K., Yanagawa, K., Osaki, N., & Shimotoyodome, A. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00268.2014 · Cited by 30
Increased effect of fucoidan on lipoprotein lipase secretion in adipocytes
Yokota, T., NAGASHIMA, M., Ghazizadeh, M., & Kawanami, O. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.01.020 · Cited by 27
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
He, F., Jin, J., Qin, Q.-Q., Zheng, Y., Li, T., Zhang, Y., & He, J.-D. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489546 · Cited by 25
Ben‐Shlomo, S., Zvibel, I., Varol, C., Spektor, L., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2013) · Obesity · doi:10.1002/oby.20340 · Cited by 28
“Furthermore, inhibition of GIP binding to its receptor using 1 lM of the GIP antagonist GIP (7-30) prevents the GIP-mediated increase in adiponectin levels (Figure 5A and 5B).”
BackgroundMethodResultInfluentialNakamura, T., Tanimoto, H., Mizuno, Y., Tsubamoto, Y., & Noda, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01555.x · Cited by 25
Prior Exercise and Postprandial Incretin Responses in Lean and Obese Individuals
Heden, T. D., Liu, Y., Kearney, M. L., Park, Y., Dellsperger, K. C., Thomas, T. R., & Kanaley, J. A. (2013) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e318294b225 · Cited by 26
“Furthermore, postprandial GIP has been shown to increase LPL activity in adipocytes (13), whereas GIP administration reduces postprandial TAG concentrations in a canine model (37).”
BackgroundYamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 40
“It promotes the clearance of triglycerides from the circulation and their subsequent storage in adipocytes by enhancing the activity of lipoprotein lipase [1,30–33].”
Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
Ying, Z., van Eenige, R., Ge, X., van Marwijk, C., Lambooij, J. M., Guigas, B., Giera, M. A., de Boer, J. F., Coşkun, T., Qu, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104684 · Cited by 28
Timper, K., Grisouard, J., Radimerski, T., Dembinski, K., Peterli, R., Häring, A., Frey, D. M., Zulewski, H., Keller, U. B., Müller-Stich, B. P., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1324 · Cited by 27
“In rodent adipocytes, GIP directly influences fat metabolism and lipid accumulation (11).”
BackgroundYamanouchi, D. (2025) · doi:10.20944/preprints202511.1408.v2 · Cited by 23
Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
Takahashi, Y., Fujita, H., Seino, Y., Hattori, S., Hidaka, S., Miyakawa, T., Suzuki, A., Waki, H., Yabe, D., Seino, Y., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13346 · Cited by 23
New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 29
Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Shang, R., & Rodrigues, B. B. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13199 · Cited by 21
Murata, Y., Harada, N., Yamane, S., Iwasaki, K., Ikeguchi, E., Kanemaru, Y., Harada, T., Sankoda, A., Shimazu‐Kuwahara, S., Joo, E., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00200.2018 · Cited by 28
“insulin resistance, HFD-induced GIP hypersecretion was considered to increase the volume of adipose tissue by binding to GIPR in the adipose tissue (23, 24, 45) and by promoting insulin secretion from pancreatic -cells under HFD feeding (34).”
BackgroundCardiovascular biology of the GIP receptor
Greenwell, A. A., Chahade, J. J., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2019.170228 · Cited by 24
Physiological Appetite Regulation and Bariatric Surgery
Ramasamy, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051347 · Cited by 27
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Ryu, A., Kim, Y., & Lee, M. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101917 · Cited by 18
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
Morrow, N. M., Hanson, A. A., & Mulvihill, E. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703966 · Cited by 19
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Protection from DIO in Gipr deficient mice is consistent with the ability of GIP to promote adipocyte lipid storage under conditions of hyperinsulinemia [40,41,97].”
Kruse, M., Keyhani‐Nejad, F., Isken, F., Nitz, B., Kretschmer, A., Reischl, E., Gala, T. D. L. H., Osterhoff, M. A., Grallert, H., & Pfeiffer, A. F. H. (2015) · Diabetes · doi:10.2337/db15-0478 · Cited by 21
Gastrointestinal regulatory peptides and their effects on fat tissue
Majumdar, I. D., & Weber, H. C. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833327dd · Cited by 18
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
Khajavi, N., Biebermann, H., Tschöp, M., & DiMarchi, R. (2017) · Endocrine Development · doi:10.1159/000475737 · Cited by 16
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
“GIP increases the activity of lipoprotein lipase [26], elevating triglyceride accumulation in fat tissue [27] and inhibiting lipolysis [28].”
BackgroundPerspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Tissue-Specific Effects of Bariatric Surgery Including Mitochondrial Function
Dankel, S. N., Staalesen, V., Bjørndal, B., Berge, R. K., Mellgren, G., & Burri, L. (2011) · Journal of Obesity · doi:10.1155/2011/435245 · Cited by 17
“In cultured human subcutaneous adipocytes, GIP together with insulin was found to activate lipoprotein lipase [45], suggesting that altered GIP levels after bariatric surgery may affect lipid uptake in adipose tissue [46].”
BackgroundNader, M. A. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0958-4 · Cited by 18
Identification and characterization of adipose surface epitopes
Onogi, Y., Khalil, A., & Ussar, S. (2020) · Biochemical Journal · doi:10.1042/bcj20190462 · Cited by 16
Kim, S., Nian, C., & McIntosh, C. H. S. (2012) · Diabetes · doi:10.2337/db12-0257 · Cited by 17
Self-citationGarcía‐Jiménez, C. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00014-x · Cited by 15
Tharp, W. G., Gupta, D., Sideleva, O., Deacon, C. F., Holst, J. J., Elahi, D., & Pratley, R. E. (2019) · Diabetes · doi:10.2337/db18-1163 · Cited by 16
“Activation of GIP-R in human adipocytes and cell lines in the presence of insulin increases lipoprotein lipase expression, promoting triglyceride storage[21, 22].”
BackgroundSanches, E. E., Timmermans, M., Topal, B., Çelik, A., Sundbom, M., Ribeiro, R. J. D. S., Parmar, C. D., Ugale, S. M., Proczko, M., Stepaniak, P. S., et al. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1690991 · Cited by 16
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“GIP significantly affects lipid metabolism in adipocytes, promoting lipolysis [ 75] and enhancing lipoprotein lipase activity [76 , 77 ].”
Yun, S.-W., Shin, Y.-J., Ma, X., & Kim, D. (2024) · Nutrients · doi:10.3390/nu16223810 · Cited by 14
Nakamura, T., Tanimoto, H., Okamoto, M., Takeuchi, M., Tsubamoto, Y., & Noda, H. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s297353 · Cited by 13
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Selective gene expression by rat gastric corpus epithelium
Goebel, M., Stengel, A., Lambrecht, N. W. G., & Sachs, G. M. (2010) · Physiological Genomics · doi:10.1152/physiolgenomics.00193.2010 · Cited by 15
Wang, T., Ma, X., Tang, T., Higuchi, K., Peng, D., Zhang, R., Chen, M., Yan, J. Y., Wang, S., Yan, D., et al. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.28 · Cited by 13
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Boer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
“In vitro studies have shown that GIP increases fatty acid uptake in adipocytes (Kim et al., 2007; Yip et al., 1998) and in humans, where infusion of GIP during a high-insulin, high-glucose clamp increased triglyceride deposition in subcutaneous adipose tissue (Asmar et al., 2010).”
BackgroundIrwin, N., Hunter, K., & Flatt, P. R. (2008) · Peptides · doi:10.1016/j.peptides.2008.01.006 · Cited by 11
Hong, S., Lee, J.-M., Park, S., Rhee, E., Park, C.-Y., Oh, K., Park, S.-W., & Lee, W.-Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.553 · Cited by 10
Tissue fibrosis associated depletion of lipid‐filled cells
Jussila, A. R., Zhang, B., Kirti, S., & Atit, R. P. (2024) · Experimental Dermatology · doi:10.1111/exd.15054 · Cited by 10
“71,131,132,133,134,135,136,137,138,139 Wnt activation in a Dpp4−/− background in vivo lead to a rescue of ECM accumulation, lipodystrophy, reduced expression of activated lipolytic proteins, and appearance of lipid breakdown by electron microscopy.”
BackgroundHosoda, Y., Okahara, F., Mori, T., Deguchi, J., Ota, N., Osaki, N., & Shimotoyodome, A. (2017) · Food & Nutrition Research · doi:10.1080/16546628.2017.1361778 · Cited by 11
“anabolic effects via GIPRs on adipocytes, including stimulation of glucose uptake, lipoprotein lipase activity [18,19], and fatty acid synthesis [20].”
BackgroundInhibition of GIP signaling extends lifespan without caloric restriction
Hoizumi, M., Sato, T. K., Shimizu, T., Kato, S., Tsukiyama, K., Narita, T., Fujita, H., Morii, T., Sassa, M. H., Seino, Y., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.036 · Cited by 10
Central Regulation of Glucose-Dependent Insulinotropic Polypeptide Secretion
Yavropoulou, M. P., & Yovos, J. G. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00006-0 · Cited by 11
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“in AMP-activated protein kinase (AMPK) phosphorylation [23].”
Lee, S., Chung, M. J., Ahn, M., Park, H. J., Wang, E. K., Guon, T., Kee, H. J., Ku, C. R., & Na, K. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122336 · Cited by 9
Min, X., Yie, J., Wang, J., Chung, B. C., Huang, C.-S., Xu, H., Yang, J., Deng, L., Lin, J., Chen, Q., et al. (2020) · mAbs · doi:10.1080/19420862.2019.1710047 · Cited by 10
Yavropoulou, M. P., Kotsa, K., Κεσίσογλου, Ι., Gotzamani-Psarakou, A., & Yovos, J. G. (2009) · Peptides · doi:10.1016/j.peptides.2009.09.029 · Cited by 9
Lyons, S. A., Lea, M. B. S., Parikh, M., Guo, Z., Kagdi, S., Bisnauth, A. R., Pitino, J. R., Ziai, S., Mir, N., Tyrrell, A. D., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00582-7 · Cited by 9
“Previous work has shown that in murine-derived differentiated pre-adipocyte 3T3-L1 cells, GIP exposure increased LPL activity in a dose-dependent manner (Eckel et al, 1979; Kim et al, 2007).”
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“GIP directly stimulates lipoprotein lipase activity [75,84] and sensitizes adipocytes to insulin [85,86] leading to efficient energy storage.”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Yang, G., Liang, X., Jiang, Y., Li, C., Zhang, Y., Zhang, X., Chang, X., Shen, Y., & Meng, X. (2022) · Aquaculture Nutrition · doi:10.1155/2022/4330251 · Cited by 7
“In adipose tissue, GIP increases glucose transporter 4 (GLUT4) and lipoprotein lipase (LPL) expression and promotes hormonesensitive lipase (HSL) activity by activating the PKA signaling pathway [21, 24].”
BackgroundLafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 8
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
“GIP activates lipoprotein lipase (Kim, Nian, & McIntosh, 2007, 2010) and promotes the uptake of fatty acids and glucose (Beck & Max, 1986; Hauner, Glatting, Kaminska, & Pfeiffer, 1988).”
Yang, G., Liang, X., Qin, C., Yang, L., Zhang, Y., Lu, R., Yan, X., Meng, X., & Nie, G. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737682 · Cited by 6
Kohda, Y., Maekita, A., Tanaka, T., & Matsumura, H. (2017) · Fundamental Toxicological Sciences · doi:10.2131/fts.4.279 · Cited by 5
“As previously reported, GIP activates lipoprotein lipase (Kim et al., 2007), suggesting that GIP expressed in the liver may be involved in gluco-lipid metabolism.”
BackgroundRetinoids and retinoid-binding proteins: Unexpected roles in metabolic disease
Blaner, W. S., Paik, J., Brun, P., & Golczak, M. (2024) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2024.10.001 · Cited by 5
Kanu, C., Boye, K. S., Poon, J. L., GOETZ, I. A., WILLIAMSON, S. E., Lou, J., Hartman, M. L., Martin, C. K., & Coşkun, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70097 · Cited by 6
Osaki, N., Suzukamo, C., Onizawa, K., Hase, T., & Shimotoyodome, A. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1216-y · Cited by 4
“Studies have shown that GIP increases the synthesis and secretion of lipoprotein lipase (LPL) in adipocytes [23, 57] and promotes the activity of LPL in fat tissue [58].”
BackgroundCataldi, S., Aprile, M., Perfetto, C., Angot, B., Cormont, M., Ciccodicola, A., Tanti, J., & Costa, V. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151320 · Cited by 4
Bolevich, S. S., Draginic, N. D., Andjic, M. M., Jeremic, N. S., Bolevich, S., Litvitskiy, P., & Jakovljevic, V. L. (2019) · Serbian Journal of Experimental and Clinical Research · doi:10.2478/sjecr-2019-0037 · Cited by 4
“What is more, GIP can purify chylomicron in the circulation by stimulating the lipoproteine lipase from adipose tissue, while GLP-1 could decrease the postprandial secretion of triacylglycerol after meal (38-40).”
BackgroundGut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“In the postprandial period, GIP enhances lipoprotein lipase-mediated clearance of chylomicron-associated TGs [221–223] and increases adipose tissue storage by facilitating FA uptake directly via GIP-R [126,218,222,224] or indirectly by augmenting insulin-mediated FA incorporation [225,226].”
Sun, Y., Huang, W., Shang, Y., El-Din, M. G. S., Hang, H., Wang, P., Zhang, C., Huang, Y., & Wang, K. (2025) · Nutrients · doi:10.3390/nu17193114 · Cited by 5
“Intriguingly, gut hormones exhibit bidirectional crosstalk with gut microbiota: microbial metabolites, such as short chain fatty acids (SCFAs) and bile acids, stimulate EECs to secrete hormones, which in turn influence hepatic AMPK activity and lipid metabolism [7–9].”
Babirak, S. P. (2023) · AACE Clinical Case Reports · doi:10.1016/j.aace.2023.05.005 · Cited by 3
Potential Health Benefits of Blackcurrants
Miller, R. J., Putnam, S. E., Edwards, M., Woodward, G., & Kay, C. D. (2013) · Wiley eBooks · doi:10.1002/9781118635551.ch10 · Cited by 5
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/822122 · Cited by 3
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
“9,39 In summary, GIP may improve energy storage by promoting the expansion of white adipose tissue, thereby reducing the risk of chronic inflammation, tissue damage, and insulin resistance caused by ectopic lipid accumulation in organs such as the liver, skeletal muscles, heart, and pancreas.”
Kohda, Y., Minamigawa, C., Matsuo, M., & Matsumura, H. (2016) · Fundamental Toxicological Sciences · doi:10.2131/fts.3.291 · Cited by 2
“Increased GIP signaling has been suggested to regulate fat metabolism within adipocytes (Yip and Wolfe, 2000; Getty-Kaushik et al., 2006; Kim et al., 2007).”
BackgroundKohda, Y. (2020) · Fundamental Toxicological Sciences · doi:10.2131/fts.7.291 · Cited by 2
“As previously reported, GIP activates lipoprotein lipase (Kim et al., 2007, 2012), suggesting that GIP expressed in the liver may be involved in glycolipid metabolism.”
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
Саприна, Т. В., Timokhina, Y. S., Мусина, Н. Н., Prokhorenko, T. S., Таширева, Л. А., & Goncharevich, O. K. (2013) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2013-3-132-147 · Cited by 2
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Kurozumi, A., Okada, Y., Satoh, H., Inoue, I., Chimori, H., Akita, E., Shiraiwa, T., Fujitani, Y., Mita, T., Gosho, M., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0386 · Cited by 1
“[26] reported that GIP in the Table 2 Comparison of changes in various parameters during meal tolerance test at baseline and 12 weeks in each group”
BackgroundKruse, M., Keyhani‐Nejad, F., Osterhoff, M. A., & Pfeiffer, A. F. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170250 · Cited by 1
Examining the regulation of adipocytokine expression during chronic insulin resistance
Hayden, E. E. (2012) · Cited by 1
An adipocentric view of the development of insulin resistance
Szalowska, E. (2011) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Mecanismos de acción de activos lipolíticos y su inactividad en la membrana celular del adipocito
Sánchez, J. R., & Riaño, J. Y. S. (2012) · doi:10.33132/23229659.313
Widenmaier, S. B. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071070
“Moreover, skeletal muscle and liver insulin resistance were reduced in obese mice with enhanced adipose tissue expansion (Kim et al., 2007a) or receiving fat transplants (Tran et al., 2008).”
BackgroundMerchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
McFadden, J. W. (2009) · VTechWorks (Virginia Tech) · Cited by 1
The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides
Hsieh, J. (2012) · TSpace (University of Toronto)
Metadata
- Authors
- Kim, S.-J., Nian, C., & McIntosh, C. H. S.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- McIntosh, Christopher H.S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 282
- Issue
- 12
- Pages
- 8557-8567
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2079889142
- Cited by
- 216
- References
- 56
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 18 · 2023: 12 · 2022: 7 · 2021: 8 · 2020: 17 · 2019: 13 · 2018: 13 · 2017: 11 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 9 · 2012: 10
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4964 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- glucose-dependent insulinotropic polypeptide, lipoprotein lipase, adipocytes, triglyceride accumulation, Akt, LKB1, AMPK, AMPK inhibition, glucagon-like peptide-1, fat metabolism, signal transduction, 3T3-L1 adipocytes, epididymal adipose tissue
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Enzyme Activation, Gastric Inhibitory Polypeptide, Glucose, Humans, Lipoprotein Lipase, Multienzyme Complexes, Rats, Zucker, Protein Serine-Threonine Kinases, Adipocytes, 3T3-L1 Cells, Proto-Oncogene Proteins c-akt, Mice, Rats, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.